Literature DB >> 29074367

Do cystic fibrosis centres with the lowest FEV1 still use the least amount of intravenous antibiotics? A registry-based comparison of intravenous antibiotic use among adult CF centres in the UK.

Zhe Hui Hoo1, Michael J Campbell2, Rachael Curley3, Stephen J Walters4, Martin J Wildman5.   

Abstract

BACKGROUND: The Epidemiologic Study of Cystic Fibrosis using 1995-1996 and 2003-2005 data found that CF centres with lowest FEV1 tended to use fewer intravenous antibiotics. We repeated the analyses using 2013-2014 UK CF registry data to determine if this was still the case.
METHODS: Analysing data for 2013 and 2014 separately, 28 adult CF centres were ranked according to median % age-adjusted FEV1. The top 7 centres were placed in the 'upper quarter' (best FEV1), the bottom 7 centres in 'lower quarter' (lowest FEV1), and the rest in 'middle half'. IV use was stratified according to %FEV1, then compared between the three groups.
RESULTS: Centres in the 'upper quarter' and 'middle half' used significantly more IV antibiotics compared to centres in the 'lower quarter' (van Elteren test P-value<0.001). Regression analyses showed that people with CF attending centres in the 'upper quarter' or 'middle half' are 30-50% more likely to receive at least one IV course per year compared to people attending centres in the 'lower quarter'.
CONCLUSIONS: CF centres with lowest FEV1 are still distinguished by lower use of intravenous antibiotics.
Copyright © 2017 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clinical epidemiology; Cystic fibrosis; Intravenous antibiotic; Pulmonary exacerbation; Registry analysis

Mesh:

Substances:

Year:  2017        PMID: 29074367     DOI: 10.1016/j.jcf.2017.10.005

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  4 in total

1.  Implementing the use of objective medication adherence data in routine clinical practice via the digital CFHealthHub platform: situation analysis and strategy development using the theoretical domains framework.

Authors:  Carla Girling; Anna Packham; Louisa Robinson; Madelynne A Arden; Daniel Hind; Martin J Wildman
Journal:  Implement Sci Commun       Date:  2022-02-08

2.  An Animated Functional Data Analysis Interface to Cluster Rapid Lung Function Decline and Enhance Center-Level Care in Cystic Fibrosis.

Authors:  Jesse Pratt; Weiji Su; Don Hayes; John P Clancy; Rhonda D Szczesniak
Journal:  J Healthc Eng       Date:  2021-05-10       Impact factor: 2.682

Review 3.  Recent advances in the understanding and management of cystic fibrosis pulmonary exacerbations.

Authors:  Kate Skolnik; Bradley S Quon
Journal:  F1000Res       Date:  2018-05-14

4.  The importance of data issues when comparing cystic fibrosis registry outcomes between countries: Are annual review FEV1 in the UK only collected when subjects are well?

Authors:  Zhe Hui Hoo; Rachael Curley; Michael J Campbell; Stephen J Walters; Martin J Wildman
Journal:  J Eval Clin Pract       Date:  2018-06-14       Impact factor: 2.431

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.